Biocon (BIOCON) Q4 24/25 earnings summary

Executive summary

• Achieved strong growth across generics, biosimilars, and research services, with robust launches and regulatory approvals in key markets, including the US and UK.

• Notable product launches include biosimilar Ustekinumab (Yesintek) in the US, Liraglutide in the UK, and Lenalidomide and Dasatinib in the US.

• Syngene acquired a US biologics facility, expanding CDMO capabilities; Peter Bains appointed CEO and MD of Syngene International.

• Audited standalone and consolidated FY25 results approved with unqualified audit opinions; final dividend of Rs. 0.50 per share recommended.

• Settlement with Regeneron secures US entry for biosimilar Aflibercept (Yesafili) by H2 2026.

Financial highlights

• Q4 FY25 operating revenue reached INR 4,417 crore, up 16% YoY; full-year revenue from operations was INR 15,262 crore, up 10% YoY.

• Core EBITDA for Q4 was INR 1,363 crore (31% margin), up 16% YoY; FY25 core EBITDA at INR 4,264 crore.

• FY25 consolidated revenue at Rs. 1,64,699 million; consolidated net profit at Rs. 14,294 million.

• Q4 FY25 net profit (before exceptional items) at ₹333 Cr, up 1391% YoY; reported net profit at ₹344 Cr.

• Exceptional gain of Rs. 6,075 million in standalone results from sale of Syngene shares.

Outlook and guidance

• Expectation of higher incremental gross margin and EBITDA from upcoming launches; focus on innovation, digital augmentation, and operational excellence.

• R&D investments to remain in the 7-9% range of revenue, aligned with product development cycles.

• Board approved raising up to Rs. 45,000 million via securities to meet financial commitments and debt obligations.

• Multiple new launches planned in FY2026, including Liraglutide in Europe and the US, and generic Copaxone.

• Peptide portfolio, especially GLP-1s, expected to drive future growth.